Acquired aplastic anemia
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1. Male or female aged >14 years; 2. Patients confirmed by clinical tests as refractory acquired aplastic anemia; 3. Have received formal treatment, including cyclosporine A (CsA), anti-human thymosin and anti-human lymphocyte globulin (ATG / ALG), androgens; 4. The treatment effect is not good, that is, according to the evaluation standard of effectiveness (Yang Chongli, Shao Zonghong. Aplastic Anemia [M] Zhang Zhinan, Shen Yan. Hematological diagnosis and efficacy standards. Version 3. Beijing: Science Press, 2007) Diagnosed as invalid or disease progression; 5. ECOG physical status score 0 to 2 points; 6. Have not participated in other clinical trials within four weeks; 7. Clinicians believe that patients do not need to initiate clinical treatment immediately.
Exclusion criteria
Exclusion criteria: 1. Suffering from other diseases that may cause whole blood cell decline and low bone marrow hematopoiesis, such as myelodysplastic syndrome (MDS), malignant blood tumors, paroxysmal nocturnal hemoglobinuria (PNH), nutritional anemia, immunity Thrombocytopenic purpura (ITP), autoimmune disease; 2. Are receiving other therapies (conflicts with this trial protocol); 3. Allergic to drugs that may be used; 4. Any medical history or concomitant disease that any investigator believes may reduce patient compliance, or interfere with the evaluation of the efficacy and safety of the test drug; 5. Major surgery will be performed within 4 weeks before the start of study treatment, or surgery will be scheduled during the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| HB;PLT;ANC;RC; | — |
Countries
China
Contacts
Department of Hematology, Second Medical Center, Chinese PLA General Hospital